Vol. 20/No. 24 | Oncology Live®

December 20, 2019

Limb preservation is now the procedure of choice for the treatment of patients with bone cancer.

December 19, 2019

Research into the mechanisms that promote resistance to immune checkpoint blockade therapies suggests the need for new strategies for patients with immunorefractory disease.

December 19, 2019

Matthew R. Smith, MD, PhD, discusses key facets of darolutamide (Nubeqa) therapy in the treatment of patients with nonmetastatic prostate cancer.

December 18, 2019

Although hereditary cancer risk was defined solely by family history in the not-so-distant past, today increasingly robust data may help define an individual’s heightened lifetime risk based on the presence of specific molecular findings within the germline

December 17, 2019

During a recent OncLive Peer Exchange® roundtable, experts discussed novel targeted agents for cholangiocarcinomas progressing through the pipeline, such as infigratinib and pemigatinib, which are selective pan-inhibitors of FGFR fusions/translocations being evaluated in phase III trials.

December 12, 2019

For the past 2 decades, clinical guidelines for the diagnosis and management of breast cancer have sought to clarify the definition of HER2 status, but several key questions remain.

December 12, 2019

Until strong findings emerged from the phase III PROfound study of PARP inhibitor olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer, targeted therapy had an uncertain foothold in this tumor type.

December 11, 2019

Investigators are attempting to advance the late-stage non–small cell lung cancer treatment paradigm by combining an emerging antimitotic modality with standard-of-care therapies in the phase III LUNAR trial.

December 11, 2019

Jeffrey S. Weber, MD, PhD, looks to earlier use of immunotherapy and novel combinations in melanoma.